3. Producción

Browse

Settings

Access type: UnknownSubject: search.filters.subject.Anesthesia

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Carbon footprint, sustainability and anesthesia. We are beginning to learn
    (Sociedad de Anestesiologia de Chile, 2022-01-01)
    Human health has been negatively impacted by the difficult environmental conditions produced by climate change. The health industry, paradoxically, generates a carbon footprint (CF) that drives climate change and represents 9.8% of the greenhouse gas (GHG) emissions in the United States (2013) and 6.3% of CF in England (2017). A considerable portion of these emissions comes from the clinical practice of anesthesia. Anesthetic gases present global warming potentials (GWPs) of up to 3,714 times higher than CO 2 throughout their life cycles, from their manufacture and use to their disposal. In this context, this review compiled and assessed the environmental impacts of the anesthetic strategy in clinical practice, making use of the life cycle analysis tool. This review describes how the anesthetic technique has a major impact on CF, through the emission of GHG expressed through tools such as the GWP 100 . As an example, at the manufacturing stage, the GWP of halogenated gases is up to 2,540 kg CO 2 eq versus 21 kg CO 2 eq for Propofol. This and other variables determine the contribution of the anesthetic technique in the emission of GHG. Finally, this review aims to help health care providers make informed decisions when considering the CH and sustainability of each anesthetic technique.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Performance assessment of a ventilator developed for emergency use in a resource-constrained ICU setting during the COVID-19 pandemic
    (BioMed Central Ltd, 2025)
    The Masi mechanical ventilator was developed in Peru, designed and manufactured as a rapid-response to the healthcare emergency. Its promising pre-clinical and clinical results allowed it to be approved by the national regulatory authority to be used during the emergency. The key features of Masi are its low manufacturing cost, low dependence on a supply of high volumes of oxygen, low oxygen consumption, and flexibility between non-invasive and invasive ventilation. While Masi lacks some of the advanced features found in commercial ICU ventilators, it was specifically designed for short-term use in resource-limited and high-demand situations as an alternative when conventional devices were unavailable. This study evaluates the survival rate in intubated COVID-19 patients ventilated with Masi as compared to other conventional ventilators.
      1